Beijing-based medical AI company InferVision completed a Series D round worth RMB 900 million (USD 139 million) from investors including Goldman Sachs, Z-Park Fund, and CCB Trust. The funds will go towards research and development as well as expanding into new overseas markets.
InferVision’s platform uses big data and AI to screen, diagnose, and treat a range of cancers, cardiovascular diseases, and infectious diseases. Founded in 2016, the company counts over 300 employees and its products have received approval in major markets like the United States, European Union, Japan, and China.
Investment in the medical AI industry has been spurred on by the pandemic, and as the sector matures, companies like Shenzhen-based Airdoc and Keya Medical are seeking an IPO on the Hong Kong Stock Exchange. While the medical AI track struggled with commercialization at first, more private and public clients are upgrading their digital infrastructure for healthcare and medical care.
In addition to supplying over 400 medical institutions across 20 countries with AI healthcare solutions, InferVision recently signed an agreement with GE Healthcare in China. The company is a participant in United Nations Global Impact, a voluntary initiative for private enterprises to implement universal sustainability principles and support the UN’s goals.
Read this: These 4 Singaporean companies are changing healthcare as we know it
36Kr Connection features translated and adapted content published by 36Kr. This article was originally written by the mononymous Dufresne for 36Kr.
